Deepnoid, First Temporary Health Insurance Listing for Brain Aneurysm AI Solution

Confirmed Number and Non-Covered Service Billing Available

Medical AI company Deepnoid announced on the 1st that its brain aneurysm diagnosis support AI solution, ‘DEEP:NEURO (Deepneuro),’ has obtained a non-reimbursable code. Medical institutions can charge patients for the service fee, and patients will receive benefits from their indemnity insurance.

With the temporary listing of Deepneuro enabling indemnity insurance benefits, it is expected to contribute to securing stable sales. Medical institutions receive fees from patients, who then bear the cost themselves but can partially recover it through indemnity medical insurance.

The demand for brain MRA examinations is also expected to help increase sales. When a brain aneurysm ruptures, it can lead to disability, aftereffects, or in severe cases, death; however, not all cases require surgery. Depending on the case, management through follow-up observation or non-surgical treatment may be possible. Patients undergo periodic MRA examinations to monitor changes in the condition of the brain aneurysm or the effectiveness of treatment.

Choi Hyun-seok, Chief Medical Officer of Deepnoid, said, "The temporary listing is expected to act as a favorable factor for entering overseas markets," adding, "It will positively impact joint research and business partnership activities currently under discussion in Singapore, Taiwan, Japan, and other countries, giving momentum to our overseas business."

Choi Woo-sik, CEO of Deepnoid, stated, "The temporary listing of Deepneuro is not only an achievement recognizing its clinical value but also an important stepping stone for increasing sales," and added, "We expect more hospitals to adopt Deepneuro due to the temporary listing." He continued, "We will continue to expand the clinical application of AI solutions and provide practical value to medical sites through ongoing innovation."

Deepneuro was designated as an innovative medical technology last year and entered the clinical market. It has been introduced in 29 hospitals to date. The number of installations is expected to increase further with the temporary listing, which is anticipated to lead to stable sales.